Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. decreased its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 7.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 42,339 shares of the biopharmaceutical company’s stock after selling 3,399 shares during the period. Harbor Capital Advisors Inc. owned approximately 0.07% of Sage Therapeutics worth $230,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in SAGE. Geode Capital Management LLC increased its holdings in shares of Sage Therapeutics by 0.3% in the third quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock valued at $8,975,000 after purchasing an additional 3,757 shares during the last quarter. State Street Corp increased its stake in shares of Sage Therapeutics by 18.2% in the 3rd quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock worth $21,127,000 after acquiring an additional 451,377 shares during the last quarter. RTW Investments LP increased its stake in shares of Sage Therapeutics by 2.0% in the 3rd quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock worth $40,372,000 after acquiring an additional 111,123 shares during the last quarter. Erste Asset Management GmbH purchased a new position in shares of Sage Therapeutics during the 3rd quarter worth $208,000. Finally, Martingale Asset Management L P boosted its position in shares of Sage Therapeutics by 55.1% during the 3rd quarter. Martingale Asset Management L P now owns 47,077 shares of the biopharmaceutical company’s stock valued at $340,000 after acquiring an additional 16,717 shares during the last quarter. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Sage Therapeutics Trading Down 0.8 %

Sage Therapeutics stock opened at $7.44 on Wednesday. The firm has a market capitalization of $455.13 million, a P/E ratio of -1.33 and a beta of 0.91. Sage Therapeutics, Inc. has a twelve month low of $4.62 and a twelve month high of $27.67. The stock’s fifty day simple moving average is $5.64 and its 200-day simple moving average is $7.53.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). The company had revenue of $11.87 million during the quarter, compared to analyst estimates of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. Sage Therapeutics’s revenue for the quarter was up 337.1% on a year-over-year basis. During the same period in the prior year, the business earned ($2.81) EPS. Sell-side analysts predict that Sage Therapeutics, Inc. will post -6.53 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SAGE has been the subject of several recent analyst reports. StockNews.com cut shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. Scotiabank reduced their price target on shares of Sage Therapeutics from $17.00 to $14.00 and set a “sector outperform” rating on the stock in a research report on Wednesday, October 30th. Royal Bank of Canada upgraded Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price objective for the company in a research report on Thursday, November 21st. Stifel Nicolaus reduced their target price on Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating on the stock in a research report on Monday, December 16th. Finally, Oppenheimer lowered their price target on Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Wednesday, October 30th. Three research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, Sage Therapeutics has an average rating of “Hold” and a consensus price target of $10.53.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.